Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Status unknown · Phase 4 · NCT06122987
Conditions: Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
At a glance
- Research payments reported, 2025
- $70,600
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Kingman Regional Medical Center (with La Jolla Pharmaceutical Company)
- Tested
- Angiotensin II and hydrocortisone sodium succinate (drug)
- Dates
- Started 2023-12-04; completion 2025-01
- Results posted
- Not yet
Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have inadequate mean arterial pressure while on norepinephrine. Uncertainty exists regarding the timing of initiation of these agents and there is a lack of data comparing their safety and efficacy. The current literature suggests that earlier initiation of angiotensin-II will have a more significant reduction on norepinephrine-equivalent dose compared to later initiation. In addition, approximately half of patients initiated on vasopressin do not have an early hemodynami…
From ClinicalTrials.gov, last updated 2024-05-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $70,600 in research payments for this study in 2025 (2 payments).
Products named: Giapreza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.